Alcolea and co-authors explored the diagnostic utility of combining NfL with AD biomarkers, specifically serum sAPPβ and YKL-40, in a cohort of patients with PSP, CBS, AD, bvFTD, and PPA and controls [112]. This evidence concerns the gene CHI3L1 and Alzheimer disease.